The antiobesity drug Orlistat induces cytotoxic effects, suppresses Her-2/neu (erbB-2) oncogene overexpression, and synergistically interacts with trastuzumab (Herceptin™) in chemoresistant ovarian cancer cells |
| |
| Authors: | J.A. MENENDEZ&dagger ,L. VELLON&dagger ,& R. LUPU&dagger |
| |
| Affiliation: | Department of Medicine, Breast Cancer Translational Research Program, Evanston Northwestern Healthcare Research Institute, Evanston, IL 60201, USA. jmenendez@enh.org |
| |
| Abstract: | Abstract. Menendez JA, Vellon L, Lupu R. The antiobesity drug Orlistat induces cytotoxic effects, suppresses Her-2/neu (erbB-2) oncogene overexpression, and synergistically interacts with trastuzumab (Herceptin™) in chemoresistant ovarian cancer cells. Int J Gynecol Cancer 2006; 16: 219–221. |
| |
| Keywords: | Orlistat Her-2/neu ovarian cancer |
|
|
